Choose FDA-approved OMIDRIA for less stressin your O.R. day

Miosis prevention with OMIDRIA superior to phenylephrine or ketorolac alone

In a phase 2b clinical trial, OMIDRIA was 4 to 6 times more effective in preventing miosis than either intracameral phenylephrine or ketorolac alone6

Percent of patients with pupil diameter <6 mm at any time during surgery6*

*

Randomized, double-masked trial using a 4-arm factorial design to show that OMIDRIA is superior to either agent alone. Post hoc analysis of pupil diameter <6 mm at any time during the procedure.

OMIDRIA consistently prevents miosis3

In pivotal phase 3 clinical trials (n=808) in which all patients received standard topical mydriatics preoperatively, OMIDRIA was superior to placebo across all assessments of pupil size. In fact, 96% of OMIDRIA-treated patients had pupil diameter ≥6 mm at the start of lens implantation.3,4,13

Pupil diameter <6 mm at start of lens implantation4,13

OMIDRIA reduces postoperative pain and use of pain medications, including opioids3,5

In two pivotal Phase 3 clinical trials in which all patients received standard anesthetic agents preoperatively, patients treated with OMIDRIA were:

Indications and Usage

OMIDRIA® is added to ophthalmic irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.

Important Safety Information

OMIDRIA must be added to irrigating solution prior to intraocular use.

OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients.

Systemic exposure of phenylephrine may cause elevations in blood pressure.

Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory drugs (NSAIDs), or have a past medical history of asthma.

Visco D. Effect of phenylephrine/ketorolac on iris fixation ring use and surgical times in patients at risk of intraoperative miosis. Clin Ophthalmol. 2018;12:301-305.

Bucci FA Jr, Michalek B, Fluet AT. Comparison of the frequency of use of a pupil expansion device with and without an intracameral phenylephrine and ketorolac injection 1%/0.3% at the time of routine cataract surgery. Clin Ophthalmol. 2017;11:1039-1043.